BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17547724)

  • 1. Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis.
    Morris KL; Tate JR; Gill D; Kennedy G; Wellwood J; Marlton P; Bird R; Mills AK; Mollee P
    Intern Med J; 2007 Jul; 37(7):456-63. PubMed ID: 17547724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
    Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
    J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.
    Lachmann HJ; Gallimore R; Gillmore JD; Carr-Smith HD; Bradwell AR; Pepys MB; Hawkins PN
    Br J Haematol; 2003 Jul; 122(1):78-84. PubMed ID: 12823348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis.
    Abraham RS; Katzmann JA; Clark RJ; Bradwell AR; Kyle RA; Gertz MA
    Am J Clin Pathol; 2003 Feb; 119(2):274-8. PubMed ID: 12579999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis.
    Mollee P; Merlini G
    Clin Chem Lab Med; 2016 Jun; 54(6):921-7. PubMed ID: 26812792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.
    Palladini G; Campana C; Klersy C; Balduini A; Vadacca G; Perfetti V; Perlini S; Obici L; Ascari E; d'Eril GM; Moratti R; Merlini G
    Circulation; 2003 May; 107(19):2440-5. PubMed ID: 12719281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunofixation electrophoresis was highly specific for the diagnosis of renal light-chain amyloidosis.
    Zhou FD; Zhang LX; Yao Y; Wang SX; Zou WZ; Liu G; Chen M; Zhao MH
    Am J Med Sci; 2013 Jan; 345(1):18-21. PubMed ID: 22627261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine.
    Palladini G; Russo P; Bosoni T; Verga L; Sarais G; Lavatelli F; Nuvolone M; Obici L; Casarini S; Donadei S; Albertini R; Righetti G; Marini M; Graziani MS; Melzi D'Eril GV; Moratti R; Merlini G
    Clin Chem; 2009 Mar; 55(3):499-504. PubMed ID: 19131635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity.
    Palladini G; Russo P; Bosoni T; Sarais G; Lavatelli F; Foli A; Bragotti LZ; Perfetti V; Obici L; Bergesio F; Albertini R; Moratti R; Merlini G
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):80-3. PubMed ID: 19362981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.
    Dispenzieri A; Lacy MQ; Katzmann JA; Rajkumar SV; Abraham RS; Hayman SR; Kumar SK; Clark R; Kyle RA; Litzow MR; Inwards DJ; Ansell SM; Micallef IM; Porrata LF; Elliott MA; Johnston PB; Greipp PR; Witzig TE; Zeldenrust SR; Russell SJ; Gastineau D; Gertz MA
    Blood; 2006 Apr; 107(8):3378-83. PubMed ID: 16397135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis.
    Bochtler T; Hegenbart U; Heiss C; Benner A; Cremer F; Volkmann M; Ludwig J; Perz JB; Ho AD; Goldschmidt H; Schonland SO
    Haematologica; 2008 Mar; 93(3):459-62. PubMed ID: 18287137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The challenge of systemic immunoglobulin light-chain amyloidosis (Al).
    Palladini G; Comenzo RL
    Subcell Biochem; 2012; 65():609-42. PubMed ID: 23225018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The clinical significance of serum free light chain in primary systemic amyloidosis].
    Zhai YP; Song P; Li F; Liu HN; Yu YP; Zhou XG; Shi P; An ZM; Zhou X; Zhang CN
    Zhonghua Nei Ke Za Zhi; 2011 May; 50(5):404-7. PubMed ID: 21624224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis.
    Akar H; Seldin DC; Magnani B; O'Hara C; Berk JL; Schoonmaker C; Cabral H; Dember LM; Sanchorawala V; Connors LH; Falk RH; Skinner M
    Amyloid; 2005 Dec; 12(4):210-5. PubMed ID: 16399645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical usefulness of serum free light chain measurement in monoclonal gammopathy].
    Shimazaki C; Murakami H; Sawamura M; Matsuda M; Kinoshita T; Hata H; Sugiura I; Tsushita K; Nagura E; Kosugi H; Itoh J; Shimizu K
    Rinsho Ketsueki; 2010 Apr; 51(4):245-52. PubMed ID: 20467220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: a pilot study.
    Kaplan B; Golderman S; Aizenbud B; Esev K; Kukuy O; Leiba M; Livneh A; Ben-Zvi I
    Am J Hematol; 2014 Sep; 89(9):882-8. PubMed ID: 24866208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Determination of light chains in serum].
    Hansen CT; Nielsen L; Münster AM; Abildgaard N
    Ugeskr Laeger; 2010 Aug; 172(34):2302-5. PubMed ID: 20727297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions.
    Graziani MS; Merlini G
    Expert Rev Mol Diagn; 2014 Jan; 14(1):55-66. PubMed ID: 24308339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Light-chain (AL) amyloidosis: diagnosis and treatment.
    Sanchorawala V
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1331-41. PubMed ID: 17699366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of the Serum Free Light Chain Assay in the Diagnosis of Light Chain Amyloidosis in Patients With Heart Failure.
    Chang IC; Dispenzieri A; Scott CG; Lin G; Jaffe AS; Klarich KW; Grogan M
    Mayo Clin Proc; 2019 Mar; 94(3):447-454. PubMed ID: 30718069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.